ClinicalTrials.gg
CompletedNCT00647543Updated Feb 18, 2021

Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand

A Phase 4 interventional study of Atorvastatin and Atorvastatin in Dyslipidemias, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 4 sites in Thailand. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
242
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.

Enrollment
20th of 47
242 · median 165
Started
2003
with 5 others
Phase 4
22 of 47
1 open now
Registered
16th of 47
by date
Lead sponsor
9 of 47
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 20th largest by enrollment, is one of 6 that started in 2003, is one of 22 in phase 4, and was the 16th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing atorvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of atorvastatin in lowering cholesterol on patients from Thailand with high cholesterol.

03

Conditions studied

  • Dyslipidemias

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dyslipidemic patients who were eligible for lipid lowering therapy
  • Willingness to follow study diet for 1 month prior to screening and for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Use of other lipid lowering agents (6-week )
  • Uncontrolled high blood pressure
  • Impaired liver function
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    High Risk

    Drug: Atorvastatin

  • Experimental
    Low Risk

    Drug: Atorvastatin

  • Experimental
    Medium Risk

    Drug: Atorvastatin

Interventions

  • Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.

  • Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.

  • Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of patients who achieved low-density lipoprotein cholesterol (LDL-C) target

    Time frame: Week 8

Secondary outcomes

  1. Adverse events and laboratory test changes

    Time frame: Weeks 2, 4, and 8

  2. Percentage of patients who achieved LDL-C target

    Time frame: Weeks 2 and 4, and Week 8 with 1 step titration

  3. Change and percent change from baseline in LDL-C

    Time frame: Weeks 2, 4, and 8

  4. Change and percent change from baseline in high-density lipoprotein cholesterol (HDL-C)

    Time frame: Weeks 2, 4, and 8

  5. Change and percent change from baseline in LDL/HDL ratio

    Time frame: Weeks 2, 4, and 8

  6. Change and percent change from baseline in total cholesterol

    Time frame: Weeks 2, 4, and 8

  7. Change and percent change from baseline in triglycerides

    Time frame: Weeks 2, 4, and 8

07

Study locations

4 sites
  • Pfizer Investigational Site
    Bangkok, 10400, Thailand
  • Pfizer Investigational Site
    Bangkok, 10700, Thailand
  • Pfizer Investigational Site
    Chiang Mai, 50200, Thailand
  • Pfizer Investigational Site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2008
First posted
Mar 31, 2008
Start
Aug 2003
CompletionActual
Apr 2004
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00647543
Responsible party
Sponsor
First posted
Mar 31, 2008
Start date
Aug 2003
Completion
Apr 2004
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion